These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


152 related items for PubMed ID: 12644730

  • 21. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
    Foster J, Brewer C, Steele T.
    Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
    [Abstract] [Full Text] [Related]

  • 22. [Methadone and naltrexone in heroin addiction--an explanation from the SBU].
    Asplund K, Jonsson E.
    Lakartidningen; 2002 Feb 07; 99(6):552-3. PubMed ID: 11881233
    [No Abstract] [Full Text] [Related]

  • 23. Naltrexone for heroin dependence treatment in St. Petersburg, Russia.
    Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.
    J Subst Abuse Treat; 2004 Jun 07; 26(4):285-94. PubMed ID: 15182893
    [Abstract] [Full Text] [Related]

  • 24. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM, Blokhina EA.
    Curr Opin Psychiatry; 2010 May 07; 23(3):210-4. PubMed ID: 20224403
    [Abstract] [Full Text] [Related]

  • 25. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.
    Brooks AC, Comer SD, Sullivan MA, Bisaga A, Carpenter KM, Raby WM, Yu E, O'Brien CP, Nunes EV.
    J Clin Psychiatry; 2010 Oct 07; 71(10):1371-8. PubMed ID: 20673549
    [Abstract] [Full Text] [Related]

  • 26. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.
    Wang AL, Elman I, Lowen SB, Blady SJ, Lynch KG, Hyatt JM, O'Brien CP, Langleben DD.
    Transl Psychiatry; 2015 Mar 17; 5(3):e531. PubMed ID: 25781230
    [Abstract] [Full Text] [Related]

  • 27. Behavioral naltrexone therapy: an integrated treatment for opiate dependence.
    Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV.
    J Subst Abuse Treat; 2002 Dec 17; 23(4):351-60. PubMed ID: 12495797
    [Abstract] [Full Text] [Related]

  • 28. Management of relapse in naltrexone maintenance for heroin dependence.
    Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV.
    Drug Alcohol Depend; 2007 Dec 01; 91(2-3):289-92. PubMed ID: 17681716
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT).
    Metrebian N, Groshkova T, Hellier J, Charles V, Martin A, Forzisi L, Lintzeris N, Zador D, Williams H, Carnwath T, Mayet S, Strang J.
    Addiction; 2015 Mar 01; 110(3):479-90. PubMed ID: 25251885
    [Abstract] [Full Text] [Related]

  • 32. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK, Morris N, Arnold-Reed D, Tait RJ.
    Arch Gen Psychiatry; 2009 Oct 01; 66(10):1108-15. PubMed ID: 19805701
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
    Collins ED, Kleber HD, Whittington RA, Heitler NE.
    JAMA; 2005 Aug 24; 294(8):903-13. PubMed ID: 16118380
    [Abstract] [Full Text] [Related]

  • 36. Does naltrexone affect craving in abstinent opioid-dependent patients?
    Dijkstra BA, De Jong CA, Bluschke SM, Krabbe PF, van der Staak CP.
    Addict Biol; 2007 Jun 24; 12(2):176-82. PubMed ID: 17508990
    [Abstract] [Full Text] [Related]

  • 37. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.
    Sylvestre DL, Clements BJ.
    Eur J Gastroenterol Hepatol; 2007 Sep 24; 19(9):741-7. PubMed ID: 17700258
    [Abstract] [Full Text] [Related]

  • 38. Predictors of dropout in an outpatient treatment for problem drinkers including cognitive-behavioral therapy and the opioid antagonist naltrexone.
    Vuoristo-Myllys S, Lahti J, Alho H, Julkunen J.
    J Stud Alcohol Drugs; 2013 Nov 24; 74(6):894-901. PubMed ID: 24172116
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
    Grinenko AIa, Krupitskiĭ EM, Zvartau EE.
    Vestn Ross Akad Med Nauk; 2003 Nov 24; (10):54-6. PubMed ID: 14598513
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 8.